Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
159 participants
INTERVENTIONAL
2000-11-30
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimization of Acute Treatment in First Episode Schizophrenia
NCT00157378
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159120
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
NCT00253110
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159133
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
NCT00249119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Maintenance antipsychotic treatment with risperidone
Haloperidol, Risperidone (drug)
targeted dose of 2-4 mg/day over 1 year
2
Maintenance antipsychotic treatment with haloperidol in low-dose
Haloperidol, Risperidone (drug)
targeted dose of 2-4 mg/day over 1 year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Haloperidol, Risperidone (drug)
targeted dose of 2-4 mg/day over 1 year
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 55
* Informed consent
Exclusion Criteria
* Legal reasons
* Insufficient knowledge of the German language
* Substance abuse or addiction
* Pregnancy
* Serious physical illness
* Organic brain disease
* Contraindication to neuroleptic treatment
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Federal Ministry of Education and Research
OTHER_GOV
German Research Network On Schizophrenia
NETWORK
Janssen-Cilag Ltd.
INDUSTRY
University of Bonn
OTHER
Humboldt-Universität zu Berlin
OTHER
University of München
OTHER
University of Göttingen
OTHER
University of Cologne
OTHER
Mainz University
OTHER
University Hospital Tuebingen
OTHER
Universität Duisburg-Essen
OTHER
University of Mannheim
OTHER
University of Jena
OTHER
Martin-Luther-Universität Halle-Wittenberg
OTHER
RWTH Aachen University
OTHER
University of Wuerzburg
OTHER
Heinrich-Heine University, Duesseldorf
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wolfgang Gaebel, Professor
Role: STUDY_CHAIR
Department of Psychiatry and Psychotherapy, University of Duesseldorf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University
Düsseldorf, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, Von Wilmsdorff M, Bottlender R, Klingberg S. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):129-40. doi: 10.1007/s00406-004-0509-y.
Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherubl MC, Kuhn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlosser R, Schmidt LG, Schmitt A, Jager M, Buchkremer G, Falkai P, Klingberg S, Kopcke W, Maier W, Hafner H, Ohmann C, Salize HJ, Schneider F, Moller HJ; German Study Group on First-Episode Schizophrenia. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007 Nov;68(11):1763-74. doi: 10.4088/jcp.v68n1116.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this study: One year maintenance treatment with low dose Haloperidol vs. Risperidone in first-episode schizophrenia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01GI 9932 - P 2.2.2.1 / 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.